Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + GEMOX in Relapsed/Refractory Hodgkin Lymphoma
NCT04239170Phase 2Unknown
- Sponsor
- Peking University
- Start
- Jan 2020
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in Hodgkin lymphoma (HL), sponsored by Peking University. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT04239170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04239170.